ITGAX and neoplasm: Of note, both the percentage of CD163+ and CD163+CD11c+ cells (Figure 5B,C) as well as their ratio to CD11c+ antigen-presenting cells (CD163+/CD11c+; Figure 5D and CD163+CD11c+/CD11c+; Figure 5E) were significantly higher in patients with PD-L1 positive expression in tumor cells.